BioPharmX Corporation, a specialty pharmaceutical company, develops and commercializes novel prescription and over-the-counter (OTC) products that address dermatology and women's health markets. The company offers VI2OLET, an OTC molecular iodine dietary supplement that addresses cyclic breast discomfort, as well as alleviates the symptoms of fibrocystic breast condition (FBC).
Read More…
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone+1-650-8895020
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees17
Next Earnings Date8/29/2019 (Estimated)
OptionableNot Optionable
Biopharmx (NYSEAMERICAN:BPMX) Frequently Asked Questions
What is Biopharmx's stock symbol?
Biopharmx trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "BPMX."
When did Biopharmx's stock split? How did Biopharmx's stock split work?
Biopharmx shares reverse split on the morning of Friday, April 26th 2019. The 1-25 reverse split was announced on Monday, April 15th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, April 25th 2019. An investor that had 100 shares of Biopharmx stock prior to the reverse split would have 4 shares after the split.
How were Biopharmx's earnings last quarter?
Biopharmx Corp (NYSEAMERICAN:BPMX) released its quarterly earnings results on Tuesday, June, 11th. The biotechnology company reported ($0.38) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.26) by $0.12. View Biopharmx's Earnings History.
When is Biopharmx's next earnings date?
What price target have analysts set for BPMX?
1 Wall Street analysts have issued 12-month target prices for Biopharmx's stock. Their forecasts range from $3.00 to $3.00. On average, they expect Biopharmx's stock price to reach $3.00 in the next year. This suggests a possible upside of 809.1% from the stock's current price. View Analyst Price Targets for Biopharmx.
What is the consensus analysts' recommendation for Biopharmx?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biopharmx in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Biopharmx.
Has Biopharmx been receiving favorable news coverage?
Press coverage about BPMX stock has trended negative recently, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Biopharmx earned a news sentiment score of -2.3 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Biopharmx.
Who are some of Biopharmx's key competitors?
Some companies that are related to Biopharmx include Ibio (IBIO), Realm Therapeutics (RLM), Bioxyne (BXN), Living Cell Technologies (LCT), Redx Pharma (REDX), Kane Biotech (KNE), Anatara Lifesciences (ANR), Naturally Splendid Enterprises (NSP), Ovoca Bio (OVB), Devonian Health Group (GSD), Briacell Therapeutics (BCT), Synairgen (SNG), Pascal Biosciences (PAS), Trillium Therapeutics (TRIL) and Hemogenyx Pharmaceuticals (HEMO).
What other stocks do shareholders of Biopharmx own?
Who are Biopharmx's key executives?
Biopharmx's management team includes the folowing people:
- Dr. David S. Tierney M.D., Pres, CEO, CFO and Director (Age 55)
- Dr. Kin Foong Chan, Exec. VP of Research & Technology (Age 45)
- Dr. José Zayas, Sr. VP of Operations
- Ms. Joyce Goto, VP, Chief Accounting Officer & Controller (Age 45)
- Ms. AnnaMarie Daniels, Exec. VP of Clinical & Regulatory Affairs
Who are Biopharmx's major shareholders?
Biopharmx's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Vivo Capital LLC (3.03%), Vanguard Group Inc. (0.75%) and Nadler Financial Group Inc. (0.52%). Company insiders that own Biopharmx stock include Anja B Krammer, David S Tierney, Stephen Morlock and Vivo Capital Viii, Llc. View Institutional Ownership Trends for Biopharmx.
Which institutional investors are selling Biopharmx stock?
BPMX stock was sold by a variety of institutional investors in the last quarter, including Vivo Capital LLC and Vanguard Group Inc.. Company insiders that have sold Biopharmx company stock in the last year include Anja B Krammer, Stephen Morlock and Vivo Capital Viii, Llc. View Insider Buying and Selling for Biopharmx.
Which institutional investors are buying Biopharmx stock?
BPMX stock was purchased by a variety of institutional investors in the last quarter, including Nadler Financial Group Inc.. Company insiders that have bought Biopharmx stock in the last two years include David S Tierney and Stephen Morlock. View Insider Buying and Selling for Biopharmx.
How do I buy shares of Biopharmx?
Shares of BPMX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Biopharmx's stock price today?
One share of BPMX stock can currently be purchased for approximately $0.33.
How big of a company is Biopharmx?
What is Biopharmx's official website?
How can I contact Biopharmx?
Biopharmx's mailing address is 1505 Adams Dr Ste D, MENLO PARK, CA 94025-1451, United States. The biotechnology company can be reached via phone at +1-650-8895020.
MarketBeat Community Rating for Biopharmx (NYSEAMERICAN BPMX)
MarketBeat's community ratings are surveys of what our community members think about Biopharmx and other stocks. Vote "Outperform" if you believe BPMX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BPMX will underperform the S&P 500 over the long term. You may vote once every thirty days.
